DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Type 1 Diabetes and the Coronavirus (COVID-19)

Those with Type 1 Diabetes (T1D) are members of an exclusive club which is more vulnerable to the effects of the Coronavirus (COVID-19), once it is contracted. Click here to learn more. We encourage you to follow the World Health Organization’s protective recommendations.

While T1D‘s are not at a greater risk of contracting the disease, it is important to take precautionary measures. These include measuring your blood glucose levels frequently and keeping them in the normal range. This will help ensure greater resistance and a faster recovery. More frequent monitoring of ketones is critical, especially if your blood glucose is elevated due to sickness, cold therapeutics containing sugar or syrup and inactivity. Steroidal decongestants are also likely to increase your blood glucose levels. Diabetic ketoacidosis (DKA) may exhibit flu-like symptoms, which is why it is important to measure ketones with test strips available from your local pharmacy or online. Additional amounts of insulin may be required under these circumstances. Contact your physician(s) immediately if you have been exposed to the virus or have symptoms.

Be sure to stock an adequate supply (a minimum of two weeks) of all your medications. For more advice managing T1D during this pandemic, please visit: https://www.jdrf.org/coronavirus/.

For the latest updates on the global impact of COVID-19 go to: https://www.worldometers.info/coronavirus/.

Learn More +

Is Cannabis Use Safe for Individuals with Type 1 Diabetes?

Cannabis use has been a hot topic in recent years with more states legalizing recreational use in addition to medicinal use. Just like any drug, cannabis has its risks and benefits which can vary from person to person depending on their individual situation.

A recent study looked at how cannabis use may impact individuals with type 1 diabetes in regard to diabetic ketoacidosis (DKA). DKA occurs when the body does not make enough insulin and ketones build up in the bloodstream due to the breakdown of fats instead of sugars.

The study found that moderate cannabis users with type 1 diabetes are twice as likely to develop DKA than non-users. Researchers used data from 932 adults who participate in the T1D Exchange clinic registry (T1DX).

It is important for individuals with T1D to understand the risks associated with using cannabis and how it can potentially affect their overall health and well-being, especially in regard to diabetes management. DKA can develop very quickly and can be potentially fatal if left untreated.

Though not involved in this study, the Diabetes Research Connection (DRC) supports early career scientists in pursuing novel research studies to advance understanding of T1D as well as improve diagnosis, treatment, and prevention strategies. Learn more about current projects and how to support these efforts by visiting http://diabetesresearchconnection.org.

 

Learn More +

Exploring the Use of Targeted Proteins in Managing Type 1 Diabetes

Currently, the most effective treatment for type 1 diabetes is the administration of insulin, but this is not a perfect solution. Since the body is unable to produce enough – or in some cases any – insulin on its own, individuals are tasked with carefully determining when and how much they need to keep blood sugar levels in check. This in itself can be challenging, and too much or too little insulin can lead to potentially life-threatening hyper- or hypoglycemia.

In addition to controlling blood sugar, insulin also helps regulate ketones within the blood. Ketones are created when lipids are broken down by the liver because the body is lacking glucose. Increased ketone levels can lead to diabetic ketoacidosis. Trouble controlling fat in the blood can put individuals at a greater risk for cardiovascular problems.

However, a recent study by researchers at the University of Geneva in Switzerland reveals that combining insulin with high doses of the protein S100A9 may improve regulation of glucose as well as lipids. Though it has only been tested in insulin-deficient diabetic mice thus far, the researchers are in the process of gaining approval for phase I human clinical trials. Other studies have already shown that there is a reduced risk of diabetes in individuals with higher levels of S100A9, so they are hopeful that this protein can play an integral role in diabetes management as well.

Another interesting discovery that the researchers made was that S100A9 was only effective when cells with TLR4 receptors were present as well. At this point, they are unsure exactly what the relationship is and why TLR4 is necessary for the process to work. However, their study leads the way toward reducing the amount of insulin necessary to effectively control blood glucose and ketone levels by combining it with the S100A9 protein.

Though not involved in this study, Diabetes Research Connection (DRC) is excited to see how it progresses once human clinical trials begin as it has the potential to impact treatment for millions of people living with type 1 diabetes. The DRC supports the advancement of research and treatment through providing critical funding to early career scientists pursuing novel research studies for the disease. Find out how to support these efforts and learn more about current projects by visiting https://diabetesresearchconnection.org.

Learn More +

Unlimited access to all the essential project updates latest diabetes research news, and more.